|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | G01N 33/574 | |
| G01N 33/74 |
| (11) | Number of the document | 2753933 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12766763.2 |
| Date of filing the European patent application | 2012-09-07 | |
| (97) | Date of publication of the European application | 2014-07-16 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/054137 |
| Date | 2012-09-07 |
| (87) | Number | WO 2013/066491 |
| Date | 2013-05-10 |
| (30) | Number | Date | Country code |
| 201161533082 P | 2011-09-09 | US |
| (72) |
WIEZOREK, Jeffrey, Scott, US
BACH, Bruce, Allen, US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, California 91320-1799,
US
|
| (54) | USE OF HUMAN PAPILLOMAVIRUS STATUS IN ESTABLISHING USE OF AN AGENT THAT BINDS EGFR IN THE TREATMENT OF CANCER |
| USE OF HUMAN PAPILLOMAVIRUS STATUS IN ESTABLISHING USE OF AN AGENT THAT BINDS EGFR IN THE TREATMENT OF CANCER |